A RANDOMIZED, CONTROLLED, OPEN-LABEL, SINGLE-CENTER, PARALLEL GROUP STUDY TO ASSESS THE EFFECT OF MIRCERA ON DELAYING DIALYSIS IN ANEMIC PATIENTS WITH STAGE 5 CHRONIC KIDNEY DISEASE NOT ON DIALYSIS

Start Date19 Mar 2019

Sponsor / Collaborator-

NCT03552393

/ CompletedPhase 2

An Open-Label, Single-Arm, Multicenter Study to Ascertain the Optimal Starting Dose of MIRCERA® Given Subcutaneously for the Maintenance Treatment of Anemia in Pediatric Patients With Chronic Kidney Disease on Dialysis or Not Yet on Dialysis.

Ascertain the starting dose of Mircera given subcutaneously for the maintenance treatment of anemia in pediatric participants with chronic kidney disease (CKD) on dialysis or not yet on dialysis when switching from stable subcutaneous (SC) maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa.

Start Date03 Aug 2018

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

NCT03427801

/ CompletedNot ApplicableIIT

Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease

An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.

Start Date01 Mar 2017

Sponsor / Collaborator

The Chinese University of Hong Kong

100 Clinical Results associated with Methoxy Polyethylene Glycol-Epoetin Beta

100 Translational Medicine associated with Methoxy Polyethylene Glycol-Epoetin Beta

100 Patents (Medical) associated with Methoxy Polyethylene Glycol-Epoetin Beta

502

Literatures (Medical) associated with Methoxy Polyethylene Glycol-Epoetin Beta

31 Dec 2025·RENAL FAILURE

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Article

Author: Zang, Xiujuan ; Huang, Xiaomin ; Ma, Yuhua ; Zhang, Chunyan ; Ruan, Yilin ; Chen, Nan ; Wang, Yi ; Yu, Geping ; Xu, Tian ; Xie, Jingyuan ; Ren, Hong ; Qi, Hualin ; Mi, Xiuhua ; Liu, Na

OBJECTIVES:

To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.

METHODS:

In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.

RESULTS:

At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.

CONCLUSIONS:

Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.

31 Mar 2025·Kidney Research and Clinical Practice

Erythropoiesis-stimulating agent responsiveness and hemoglobin variability is associated with fat tissue index in hemodialysis patients with darbepoetin-alfa treatment: a prospective observational cohort study

Article

Author: Yu, Hyokyeong ; Kim, Do Hyoung ; Oh, Dong-Jin

Background: Although the introduction of erythropoietin-stimulating agents (ESAs) has led to better clinical outcomes in patients undergoing hemodialysis (HD), fluctuations in hemoglobin (Hb) levels, known as Hb variability, are frequently observed. However, only a few studies have evaluated the association between Hb variability and nutritional status in patients undergoing HD. Methods: In this prospective study conducted between March 1, 2020, and June 1, 2022, we included 109 patients aged over 20 years undergoing HD and receiving darbepoetin. We checked the average NESP (darbepoetin-alfa; Kyowa Kirin Korea Co., Ltd.) dose weekly and nutritional parameters such as body mass index (BMI), fat tissue index (FTI), and lean tissue index obtained by body composition monitoring. Additionally, the ESA resistance index (ERI) and the coefficient of variation of Hb (Hb-CV) were evaluated. Results: In this study, the mean age of the patients was 64.0 ± 11.9 years, and 55.0% were male. Mean Hb was 10.7 ± 1.3 g/dL. Patients were categorized into three groups according to the ERI or Hb-CV tertiles. The highest ERI tertile was associated with lower Hb levels, BMI, and FTI. The highest Hb-CV tertile was associated with lower BMI and FTI. In multiple linear regression analysis, FTI was negatively associated with ERI (β = –0.218, p = 0.01) and Hb-CV (β = –0.181, p = 0.04). Conclusion: These findings suggest that FTI is negatively associated with ERI and Hb-CV, and that ESAs responsiveness and Hb variability are associated with FTI in patients undergoing HD with darbepoetin treatment.

01 Feb 2025·JACC. Advances

Finerenone Efficacy in Patients with Chronic Kidney Disease, Type 2 Diabetes, and Anemia in FIDELITY

Article

Author: Anker, Stefan D ; Farjat, Alfredo E ; Pitt, Bertram ; Filippatos, Gerasimos ; Rossing, Peter ; Roberts, Luke ; Ruilope, Luis M ; Singh, Ajay K ; James, Glen ; Farag, Youssef M K

BACKGROUND:

Anemia is common in patients with chronic kidney disease and type 2 diabetes. Finerenone improved heart and kidney outcomes in patients with chronic kidney disease and type 2 diabetes in FIDELITY.

OBJECTIVES:

This post hoc analysis investigated the efficacy and safety of finerenone vs placebo by baseline anemia status.

METHODS:

Anemia was defined as serum hemoglobin levels <13 g/dL (male) or <12 g/dL (female) or treatment with an erythropoiesis-stimulating agent at baseline. Outcomes included cardiovascular (CV) and kidney composites, hospitalization for heart failure, and all-cause mortality. Safety was assessed through treatment-emergent adverse events.

RESULTS:

Of 12,971 patients, 33% had anemia at baseline. Finerenone reduced the risk of the CV composite outcome to a greater extent in patients with vs without anemia (HR: 0.75 [95% CI: 0.65-0.88] vs HR: 0.93 [95% CI: 0.82-1.05]; P for interaction = 0.03). Finerenone reduced the risk of the kidney composite outcome vs placebo, with no heterogeneity between patients with vs without anemia (HR: 0.79 [95% CI: 0.65-0.95] and HR: 0.74 [95% CI: 0.60-0.91]; P for interaction = 0.77). The risk of hospitalization for heart failure and all-cause mortality was lower with finerenone vs placebo, irrespective of anemia status. Patients with anemia experienced higher incidence of treatment-emergent hyperkalemia vs those without.

CONCLUSIONS:

Finerenone demonstrated CV and kidney benefit in patients with and without anemia. The benefit of finerenone on CV outcomes was greater in patients with vs without anemia at baseline. Anemia is likely a marker for higher-risk patients who are more susceptible to the benefits of finerenone. (Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease [FIDELIO-DKD], NCT02540993; Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease [FIGARO-DKD], NCT02545049).

News (Medical) associated with Methoxy Polyethylene Glycol-Epoetin Beta

24 Oct 2024

·www.prnewswire.com

Fresenius Medical Care Recent Study Validates Innovative Anemia Therapy Software Improves Clinical Outcomes for Hemodialysis Patients

This randomized controlled study demonstrates that patients achieved a higher percentage of target hemoglobin levels Patients receiving anemia management assistance via the software tools saw a 25% reduction in erythropoiesis-stimulating agent (ESA) usage The software's physiology-based model and predictive controller were associated with improved hemoglobin fluctuations and variability, offering a higher likelihood of more stable hemoglobin levels compared to standard care protocols BAD HOMBURG, Germany, Oct. 24, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced innovative results from a multicenter, randomized controlled trial in the United States that highlights the potential benefits of personalized anemia therapy for patients undergoing hemodialysis. The study, "Effects of Individualized Anemia Therapy on Hemoglobin Stability," published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrates that the use the anemia therapy assistance software, attained improved hemoglobin stability and reduced the use of erythropoiesis-stimulating agents (ESAs) among hemodialysis patients participating in the study1. This innovative approach, which is part of the company's ongoing commitment to improve patient outcomes, is powered by a physiology-driven mathematical model designed to deliver personalized treatment recommendations. The results showed a 25% improvement in hemoglobin target attainment for patients receiving individualized therapy compared to standard care. The findings are significant because maintaining target hemoglobin levels with less variability in patients can help reduce the risk of developing cardiovascular problems. "This study exemplifies how data-driven insights can lead to more personalized treatments," said Dr. Frank Maddux, MD, Chief Global Medical Officer of Fresenius Medical Care. "By integrating cutting-edge computational techniques, we are paving the way for more precise, patient-centered care, which not only improves clinical outcomes but also enhances quality of life for people on dialysis. Our commitment is to continue developing innovative solutions that transform kidney care worldwide." The study, conducted by Dr. Doris H. Fuertinger and colleagues, enrolled 96 patients from five Fresenius Kidney Care clinics across the United States. Patients were randomized into two groups: one receiving personalized anemia treatment recommendations from the software, and the other following standard protocols. Over a 26-week period, patients in the personalized therapy group achieved greater hemoglobin stability, experienced fewer fluctuations, and required significantly less ESA, reducing their dose on average by 25%. Additional key findings suggest hemoglobin variability was significantly lower in the personalized therapy group, contributing to more stable patient outcomes. "This prospective, randomized controlled study highlights the value of physiological models and computer-aided individualization of therapy to improve clinical outcomes for people on dialysis," said Dr. Fuertinger, Head of Computational Medicine, Fresenius Medical Care. "By harnessing the power of these technologies, we are able to provide clinicians with actionable insights that may enable more precise and efficient therapy management." The study underscores FME's vision of transforming renal care by designing cloud-based technologies and predictive analytics that can potentially integrate into daily clinical practice. As healthcare moves toward greater personalization, the company is committed to utilizing these advanced tools to optimize patient care and support clinicians in making data-driven decisions. "We are proud to be at the forefront of this important research by developing novel approaches to treat end-stage renal failure," said Dr. Katarzyna Mazur-Hofsaess, member of the Management Board of Fresenius Medical Care and responsible for the segment Care Enablement. "Our commitment to new technology continues to support the individualization of care for people living with kidney disease." For more information on Fresenius Medical Care's innovations and research in renal care, visit . About Fresenius Medical Care: Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.1 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,757 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 311,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the Company's website at . Disclaimer: This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to the COVID-19 pandemic results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release. 1 Fuertinger, Doris H., et al. "Effects of Individualized Anemia Therapy on Clinical Outcomes in Patients Undergoing Hemodialysis." Clinical Journal of the American Society of Nephrology, vol. 19, no. 9, 2024, pp. 1100-1110. Media contact Kirsten Stratton T +1 781 929 8096 [email protected] Christine Peters T +49 160 60 66 770 [email protected] Contact for analysts and investors Dr. Dominik Heger T +49 6172 609 2601 [email protected] SOURCE Fresenius Medical Care Holdings, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Result

13 Feb 2024

·www.businesswire.com

Injectable Hematology Growth Factors Report 2024 - Evolution in Therapeutic Care - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering. This report is a comprehensive evaluation and analysis of the technology, products, and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision-makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, and opportunities for injection devices designed for patient self-administration. Provider organization business managers, healthcare administrators, and investors will also benefit from this study. Evolution in Therapeutic Care Several recombinant hematologic growth factors or agonists for their receptors have been produced that are useful in treating anemia, neutropenia, and thrombocytopenia, particularly in patients with end-stage renal disease or aplastic anemia or who have received cancer chemotherapy or a hematopoietic cell transplant. The shift in as-supplied packaging from single and multi-use vials to prefilled injection devices will accelerate over the next five years as drug developers move to empower an increasing number of chronically ill patients. The powerful physiological effects of antibodies, hormones, and other biological drugs also increase the need for safety and compliance. What You Will Learn Provides detailed analysis of injectable hematology growth factors delivery and device strategies, and product development factors. Assesses key markets, market dynamics, and market demographics. Analyzes therapeutic demand drivers and evaluates injectable drug products in a number of key therapeutic segments. Provides market data and forecasts. Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations Assesses the importance of alliances and partnerships on drug product commercialization. Evaluates the impact of economic, technology, and regulatory factors Key Topics Covered: Hematology Market Dynamics Competitive Factors Proliferation of Biological Drugs Product Manufacturers Hematology Growth Factors Devices for Administering Injectable Growth Factors Device Selection - Stability and Material Issues Competitive Landscape Prefilled Syringes Pen Injectors Dual Chamber Pens Emerging Devices Injectable Hematology Growth Factors - Product Assessment Abseamed Accofil Aranesp Binocrit Biograstim Biopoin Epoetin Alfa Hexal Eporatio Filgrastim Hexal Fulphila Granix Grastofil Mircera NeoRecormon Neulasta Neupogen Nivestim Ratiograstim Retacrit Rolvedon Silapo Tevagrastim Udenyca (Coherus BioSciences) Zarzio Ziextenzo Market Assessment Anemia Hematopoietic Stem Cell Transplant Advanced Kidney Disease Neutropenia Predonation of Autologous Blood Company Profiles Companies Mentioned AbZ-Pharma Accord Healthcare Amgen Genentech Hexal AG Medice Arzneimittel Mylan International Novartis Pfizer Ratiopharm Rentscler Biotechnologie Roche Sandoz Stada Arzneimittel AG Teva Pharmaceuticals For more information about this report visit https://www.researchandmarkets.com/r/bktosb About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ASH

09 Feb 2024

·www.prnewswire.com

Injectable Hematology Growth Factors Report: Shift in As-Supplied Packaging from Single and Multi-use Vials to Prefilled Injection Devices will Accelerate over the Next Five Years

DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Injectable Hematology Growth Factors Report" has been added to ResearchAndMarkets.com's offering. Understanding the rapidly advancing sector of injectable hematology growth factors is crucial for stakeholders in the healthcare industry. The latest comprehensive report evaluates the intersection of technology, products, and key players that are shaping this dynamic segment, with particular emphasis on devices designed for patient self-administration. The study presents an in-depth examination of the evolving therapeutic care landscape, highlighting significant developments in the treatment of conditions such as anemia, neutropenia, and thrombocytopenia. It analyzes the shift from traditional vials to prefilled injection devices, a trend that is likely to gain momentum over the following five years, emphasizing the market forces driving this change. Key Highlights from the Report: An in-depth analysis of device strategies and product development factors influencing the injectable hematology growth factors delivery systems. Insight into market dynamics and demographics, underpinning industry growth. An evaluation of therapeutic demand drivers across pivotal segments in healthcare. Comprehensive market data and forecast trends to inform strategic decisions. Profiles of sector participants including business strategies and corporate associations. An assessment of how alliances and partnerships affect the commercialization of drug products. Insights into the economic, technological, and regulatory factors impacting the market. Healthcare administrators, investors, and other stakeholders will benefit from this study's findings that not only chart current market conditions but also project future industry directions. It serves as a critical resource for decision-makers aiming to understand and capitalize on the opportunities presented within this segment. The report's findings are pivotal for a broad spectrum of healthcare professionals, including pharmaceutical decision-makers, device developers, healthcare marketers, and supply chain entities. It is particularly geared towards empowering chronically ill patients and enhancing safety protocols through revolutionary drug delivery methods. Stakeholders are poised to gain substantial insights into the strategies propelling the adoption of injectable hematologic treatments, facilitating informed decisions that align with the compelling trends of self-administered therapeutic care. Discover the Future of Injectable Hematology Treatments As the healthcare industry continues its inexorable march towards more patient-centric and self-managed treatment options, understanding the nuances and intricacies of injectable hematology growth factor treatments becomes ever more critical. The recent report provides these vital insights, demarking a clear view of the path forward. Stay informed on the latest in healthcare advancements and market opportunities. For further information and to explore the depth of this report, interested parties are encouraged to delve into the comprehensive analysis that awaits them. Key Topics Covered: Hematology Market Dynamics Competitive Factors Proliferation of Biological Drugs Product Manufacturers Hematology Growth Factors Devices for Administering Injectable Growth Factors Device Selection - Stability and Material Issues Competitive Landscape Prefilled Syringes Pen Injectors Dual Chamber Pens Emerging Devices Injectable Hematology Growth Factors - Product Assessment Abseamed Accofil Aranesp Binocrit Biograstim Biopoin Epoetin Alfa Hexal Eporatio Filgrastim Hexal Fulphila Granix Grastofil Mircera NeoRecormon Neulasta Neupogen Nivestim Ratiograstim Retacrit Rolvedon Silapo Tevagrastim Udenyca (Coherus BioSciences) Zarzio Ziextenzo Market Assessment Anemia Hematopoietic Stem Cell Transplant Advanced Kidney Disease Neutropenia Predonation of Autologous Blood Company Profiles Companies Mentioned AbZ-Pharma Accord Healthcare Amgen Genentech Hexal AG Medice Arzneimittel Mylan International Novartis Pfizer Ratiopharm Rentscler Biotechnologie Roche Sandoz Stada Arzneimittel AG Teva Pharmaceuticals For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

ASH

100 Deals associated with Methoxy Polyethylene Glycol-Epoetin Beta

External Link

KEGG	Wiki	ATC	Drug Bank
-	Methoxy Polyethylene Glycol-Epoetin Beta	B03XA03	DB09107

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia	China	Roche Pharma (Schweiz) AG	28 Apr 2018
Anemia of renal disease	Japan	Chugai Pharmaceutical Co., Ltd.	22 Apr 2011
Anemia in chronic kidney disease	Australia	Roche Products Pty Ltd.	28 Jul 2009
chronic renal failure anemia	European Union	Roche Registration GmbH	20 Jul 2007
chronic renal failure anemia	Iceland	Roche Registration GmbH	20 Jul 2007
chronic renal failure anemia	Liechtenstein	Roche Registration GmbH	20 Jul 2007
chronic renal failure anemia	Norway	Roche Registration GmbH	20 Jul 2007

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic kidney disease, Stage V	Phase 3	United States	Hoffmann-La Roche, Inc.	01 Mar 2007
Peritoneal dialysis complication	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	01 Feb 2007
Nephrosis	Phase 3	Japan	Chugai Pharmaceutical Co., Ltd.	01 Jan 2007
Chronic Kidney Diseases	Phase 3	United States	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	Brazil	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	Canada	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	Czechia	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	France	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	Germany	Hoffmann-La Roche, Inc.	01 Feb 2004
Chronic Kidney Diseases	Phase 3	Greece	Hoffmann-La Roche, Inc.	01 Feb 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ISN WCN2023	Not Applicable	Chronic Kidney Diseases hemoglobin \| eGFR	225	CERA	qczalesydx(xytsiltmiu) = jrknavyqwv sgnndezyxt (cscmcfbrcu, 1.05) View more	Positive	01 Mar 2023
CROWNWeb (ASN2022)	Not Applicable	Maintenance erythropoietin resistance index (ERI) \| hemoglobin (Hb) \| transferrin saturation (TSAT)	-	Epoetin alfa (EPO)	epdapgexzl(icgmargkbg) = vccguhloqk rimcuopphc (ptxnedniqs ) View more	-	03 Nov 2022
				Darbepoetin alfa (DPO)	epdapgexzl(icgmargkbg) = sdzqaeewgw rimcuopphc (ptxnedniqs ) View more
NCT03552393 (SKIPPER, ERA2022)	Phase 2	Anemia in chronic kidney disease Maintenance	-	C.E.R.A. SC every 4 weeks	syyxpqnkyf(lijlxjiaqp) = dpgawoutdx vzhgzpkqls (ittojjrhls, 1.03) View more	Positive	03 May 2022
MH40258 (ERA2022)	Not Applicable	Anemia in chronic kidney disease	229	C.E.R.A. (Continuous Erythropoietin Receptor Activator—Methoxy Polyethylene Glycol Epoetin Beta) (Peritoneal Dialysis (PD))	eqferlfkiw(qrknbkaqwg) = 121 PD patients (68%) and 36 HD patients (69%) had ≥ 1 hospitalization, of whom 102/121 (84%) and 32/36 (89%), respectively, had non-elective hospitalizations. Median hospitalization surveillance time/patient was 13.5 months in the PD and 18.3 months in the HD cohorts. The most frequent causes for non-elective hospitalization were infections, reported as a cause in 56/177 (32%) patients in the PD cohort and 14/52 (27%) in the HD cohort and technique complications, in 41/177 (23%) patients in the PD cohort and 20/52 (38%) in the HD cohort. jkytxizabn (loycsvjthf ) View more	Positive	03 May 2022
				C.E.R.A. (Continuous Erythropoietin Receptor Activator—Methoxy Polyethylene Glycol Epoetin Beta) (Hemodialysis (HD))
NCT03552393 (SKIPPER, CTgov)	Phase 2	Anemia \| Chronic Kidney Diseases	40	Mircera	zplzbfjcms(iysvdpdngb) = vebxoiwxuj lvdjbgzfxt (cyjaynyedl, 0.51) View more	-	07 Mar 2022
ASN2021	Not Applicable	-	260	IV PEG-epoetin beta	cpwbsvgths(fxdjoxplpw) = azsrjwdxfw savoxpfcki (lyyavuivcu ) View more	Positive	27 Oct 2021
				sc epoetin beta	cpwbsvgths(fxdjoxplpw) = ypqpaprkjo savoxpfcki (lyyavuivcu ) View more
OptumLabs Data Warehouse (ASN2020)	Not Applicable	Anemia hemoglobin \| eGFR \| diabetes ... View more	-	Erythropoiesis-Stimulating Agent (CKD stages G1-2)	idayedeseo(llybelrddk) = lycfzugitq srutspqpfk (fhtzmjukwh )	Positive	19 Oct 2020
				Erythropoiesis-Stimulating Agent (CKD stage G3a)	idayedeseo(llybelrddk) = wtwrukbhgd srutspqpfk (fhtzmjukwh )
PARAMOUNT-HD (ERA2020)	Not Applicable	Maintenance	4,034	CERA	ogdfwxyylt(tqrhzhphef) = pgueqgunjy ivdaybbnhq (uolprzbpvu )	Positive	06 Jun 2020
ASN2019	Not Applicable	EPCs \| vascular endothelial growth factor \| matrix metalloproteinase-2 (MMP-2) ... View more	42	Recombinant human erythropoietin (rhEPO)	mipsjrubge(rdatqnltzj) = euyusmpgod wgpstvsuxl (bvazvmnzai )	-	05 Nov 2019
				Darbepoetin (DA)	mipsjrubge(rdatqnltzj) = tdflwstkql wgpstvsuxl (bvazvmnzai )
PARAMOUNT-HD (ASN2019)	Not Applicable	Maintenance hemoglobin	304	Epoetin Beta Pegol (Proactive treatment group (target Hb level: 11g/dL))	vxcsdeghwl(bwlhsmxmfb) = lwqsgxxipz jtkjsfpskm (gbttdtdozo ) View more	Positive	05 Nov 2019
				Epoetin Beta Pegol (Maintenance treatment group (target Hb level: 9-10g/dL))	vxcsdeghwl(bwlhsmxmfb) = egpjecarbf jtkjsfpskm (gbttdtdozo ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis